



(51) International Patent Classification:

C07D 333/22 (2006.01) A61K 31/381 (2006.01)
C07D 409/04 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:

PCT/IB2012/050806

(22) International Filing Date:

22 February 2012 (22.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

242/KOL/2011 23 February 2011 (23.02.2011) IN
1184/KOL/2011 9 September 2011 (09.09.2011) IN

(71) Applicant (for all designated States except US): **LUPIN LIMITED** [IN/IN]; 159 CST Road, Kalina, Santacruz (East), State of Maharashtra, Mumbai 400 098 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SINHA, Neelima** [IN/IN]; Lupin Limited (Research Park), 46A/47A, Village Nande, Taluka Mulshi, Maharashtra, Pune 411 042 (IN). **JANA, Gourhari** [IN/IN]; Lupin Limited (Research Park), 46A/47A, Village Nande, Taluka Mulshi, Maharashtra, Pune 411 042 (IN). **SACHCHIDANAND, Sachchidanand** [IN/IN]; Lupin Limited (Research Park), 46A/47A, Village Nande, Taluka Mulshi, Maharashtra, Pune 411 042 (IN). **KURHADE, Sanjay, Pralhad** [IN/IN]; Lupin Limited (Research Park), 46A/47A, Village Nande, Taluka Mulshi, Maharashtra, Pune 411 042 (IN). **KARCHE, Navnath, Popat** [IN/IN]; Lupin Limited (Research Park), 46A/47A, Village Nande, Taluka Mulshi, Maharashtra, Pune 411 042 (IN). **HAJARE, Anil, Kashiram** [IN/IN]; Lupin Limited (Research Park), 46A/47A, Village Nande, Taluka Mulshi, Maharashtra, Pune 411 042 (IN). **TILEKAR, Ajay, Ramchandra** [IN/IN]; Lupin Limited (Research Park), 46A/47A Village Nande, Taluka Mulshi, Maharashtra, Pune 411 042 (IN). **PALLE, Venkata, P.** [US/IN]; Lupin Limited (Research Park), 46A/47A, Vil-

lage Nande, Taluka Mulshi, Maharashtra, Pune 411 042 (IN). **KAMBOJ, Rajender, Kumar** [CA/IN]; Lupin Limited (Research Park), 46A/47A, Village Nande, Taluka Mulshi, Maharashtra, Pune 411 042 (IN).

(74) Agents: **MAJUMDAR, Subhatosh** et al.; S. Majumdar & Co., 5, Harish Mukherjee Road, Kolkata 700 025 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS



(57) Abstract: Disclosed is a compound of formula (I), wherein Z, m and R¹-R⁶ are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the α7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereof, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.